Barinthus Biotherapeutics (FRA:2AB) EV-to-Revenue: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2AB Barinthus Biotherapeutics PLC FRA:2AB
38 GF Score
Price €0.60
GF Value €0.90
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Barinthus Biotherapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Barinthus Biotherapeutics's enterprise value is €-17.93 Mil. Barinthus Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil. Therefore, Barinthus Biotherapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Barinthus Biotherapeutics's EV-to-Revenue or its related term are showing as below:

During the past 7 years, the highest EV-to-Revenue of Barinthus Biotherapeutics was 785.65. The lowest was -213.25. And the median was -2.96.

FRA:2AB's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 8.725
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2026-08-31), Barinthus Biotherapeutics's stock price is €0.595. Barinthus Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00. Therefore, Barinthus Biotherapeutics's PS Ratio for today is .

Barinthus Biotherapeutics  (FRA:2AB) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Barinthus Biotherapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.595/0
=

Barinthus Biotherapeutics's share price for today is €0.595.
Barinthus Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics EV-to-Revenue Related Terms

Barinthus Biotherapeutics EV-to-Revenue Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics EV-to-Revenue Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-Revenue
Get a 7-Day Free Trial 771.55 -2.16 17.07 -3.34 0.00

Barinthus Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 0.00 0.00 0.00 0.00

FRA:2AB vs ESLA, NNVC, ATNM: EV-to-Revenue Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics EV-to-Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's EV-to-Revenue falls into.


FRA:2AB
38GF Score
Barinthus Biotherapeutics PLC FRA:2AB
EV-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Barinthus Biotherapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-17.934/0
=

Barinthus Biotherapeutics's current Enterprise Value is €-17.93 Mil.
Barinthus Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Barinthus Biotherapeutics (FRA:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.60 is trading 33.9% below its estimated GF Value™ of €0.90. GuruFocus considers Barinthus Biotherapeutics to be Possible Value Trap.

Key valuation signals for FRA:2AB:

  • EV-to-Revenue:
  • GF Value™: €0.90 vs. price of €0.60 (33.9% below fair value)
  • GF Score™: 38/100 with 2 warning signs

No single metric tells the full story. See the FRA:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
38GF Score

Get the complete analysis for FRA:2AB

EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.60
Price
€0.90
GF Value